Navigation Links
Researchers: Molecular forklifts overcome obstacle to 'smart dust'
Date:1/18/2009

GAINESVILLE, Fla. --- Algae is a livid green giveaway of nutrient pollution in a lake. Scientists would love to reproduce that action in tiny particles that would turn different colors if exposed to biological weapons, food spoilage or signs of poor health in the blood.

Now, University of Florida engineering researchers have tapped the working parts of cells to clear a major hurdle to creating such "smart dust." The feat, which signifies a new approach to technology known as the "lab on a chip," is to be reported Sunday in the journal Nature Nanotechnology.

"Instead of just changing one part of an existing system, we have a new and different way of doing things," said Henry Hess, a UF assistant professor of materials science and engineering and the senior author of the paper. "And we can do it this way because of building blocks from bionanotechnology, and that's what makes it very exciting."

Chip-based labs have been developed in recent years as portable tools to gauge the presence of bioweapons, pollution, or to conduct on-the-spot blood tests. They are essentially assays, or ways to test for different pathogens, chemicals or compounds.

Scientists have suggested that the ever-shrinking labs could be reduced to the size of tiny particles of "smart" dust. But although today's versions may be small, they require equipment that is hand-held at its smallest, and often large enough to require a lab bench.

"It's like a computer," Hess said. "The central processing unit is the really interesting thing, but you need all this other stuff to make it work."

The extra equipment is needed because the assay, which uses pairs of antibodies to latch onto target contaminants and the markers that give away their presence, requires repeated flushing with water. That requires pumps, which need power. To miniaturize the system, it's necessary to build miniature pumps and batteries. But that's a challenge, especially for
'/>"/>

Contact: Henry Hess
hhess@mse.ufl.edu
352-846-3781
University of Florida
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia
2. Fast molecular rearrangements hold key to plastics toughness
3. Imaging in Living Color with Siemens Molecular CT
4. Fast molecular rearrangements hold key to plastic’s toughness
5. China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits
6. Miniaturizing memory: Taking data storage to the molecular level
7. Former Telomolecular CEO Clarifies SEC Settlement
8. Data Presented at Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests
9. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
10. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
11. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ael, December 2 Gamida Cell announ...inical (animal study) safety and,efficacy of a gen...eill,Cornell Medical College and Gamida Cell. The ...ias such as Cooley,s Anemia. , Gamida Cel..., ex vivo,populations of stem/progenitor cells. T...
(Date:12/2/2009)...wswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ:...armaceutical company focused on endocrine therapy ...nd Drug Administration (FDA) has granted Fast Trac...nhibitor compound, perifosine (KRX-0401), for the ... Keryx Biopharmaceuticals, Inc. ("Keryx") ( KERX),...
(Date:12/1/2009)...olomon announced that he has joined Carolina Eyeca...ite at www.DrKerrySolomon.com , which was develop...proven LASIK, lens implant, and cataract surgery e...is substantial contributions to improving vision c...K Surgeons, which screens LASIK surgeons based upo...
(Date:12/1/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, Emerging Clinical Trial Locations - E...althcare and regulatory environment ,, http:/...rial-Locations---Eastern-Europe-Market-dynamics-an...nt.html ,, Over the last decade pharmaceutical...
Breaking Biology Technology:Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8
...L, Inc. (Amex:,ADL), headquartered in Tustin, Cali...ilin, China, through its wholly owned subsidiary J... biopharma company that,together with JPI, engages...proprietary pharmaceutical, health care and diagno...I,s subsidiary, JJB, won a supply contract,for the...
... Pharmaceuticals,Inc. (Amex: ANX ), a biopharmace... commercializing proprietary product candidates fo... announced today that Evan M. Levine, the,company,... position as,Chief Executive Officer and President...eptember 2006., The company also announced that J...
...re-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NA...ceutical and,medical device company, is scheduled ...eutical, Biotechnology and Medical Device Conferen...NY., Dr. William Hunter, Angiotech,s President an...on Tuesday, February 5, at the Grand Hyatt New,Yor...
Other Biology Technology:AMDL Wins Chinese Military Supply Agreement for Its Domperidone Product for up to $6.6 Million 2ADVENTRX Announces Consolidation of Clinical and Management Positions 2ADVENTRX Announces Consolidation of Clinical and Management Positions 3
(Date:12/1/2009)...ner of the 2009 Inserm Grand Prix., Every year s...aying tribute to outstanding,work performed in it...ts, Inserm intends to,demonstrate the diversity a...ical, medical and,health research, and the creati...t and,drive this research each day. The Inserm 20...
(Date:12/1/2009)...t-and-run attacks by sharks can be solved with a n...nique chomp they put on their victims, according t...ert. , In a method analogous to analyzing human ...by precisely comparing shark bites to the jaws and...ess, director of the International Shark Attack Fi...
(Date:12/1/2009)...onash University-led international research team h... of the next generation of solar cells. , Scient...olleagues from the universities of Wollongong and ...d solar cells with a three-fold increase in energy...ported tandem dye-sensitised solar cells. , Lea...
Breaking Biology News(10 mins):Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3Innovation puts next-generation solar cells on the horizon 2Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 1Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 2Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 3Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 4Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 5Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 6Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 7Abbott HIV Test Demonstrates Earlier Disease Detection 13141 1Abbott HIV Test Demonstrates Earlier Disease Detection 13141 2Abbott HIV Test Demonstrates Earlier Disease Detection 13141 3Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 1Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 2Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 3Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 4Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 5
...ational team of Mayo Clinic-led researchers is fir...he measles virus into a therapeutic killer that hu...ells only. Their research findings appear as an ad... , The researchers harnessed the viral trait for ...cted the virus to attack diseased, rather than hea...
...ing the value of good prenatal care, new research ...ve vulnerability that appears later during stress ...y of Colorado at Boulder have reported that rats w...dn,t learn as well as adult rats who were not infe... The research is in February,s Behavioral Neurosci...
...ng animals, Johns Hopkins researchers have discove...eviate HIV,s negative effects on the brain and cen...n though antiretroviral therapy controls the virus...ith simian immunodeficiency virus (SIV), a very cl...had less damage to brain cells, less brain inflamm...
Other Biology News:Mayo Clinic Researchers Create 'Obedient Virus'; First Step To Use Measles Virus Against Cancer 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 3Antibiotic might fight HIV-induced neurological problems 2Antibiotic might fight HIV-induced neurological problems 3
Yeast Nitrogen Base from Invitrogen
Streptavidin, PE conjugated/tagged from Invitrogen
Rabbit Anti-Human PVRL2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
GIBCO AmnioMAX-C100 Basal Medium liquid from Invitrogen
Biology Products: